晚期乳腺癌患者中他莫昔芬及其代谢产物的血清消除半衰期
Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.
作者信息
de Vos D, Slee P H, Stevenson D, Briggs R J
机构信息
Medical Department, Pharmachemie B.V., Haarlem, The Netherlands.
出版信息
Cancer Chemother Pharmacol. 1992;31(1):76-8. doi: 10.1007/BF00695998.
PMID:1458563
Abstract
In breast cancer patients discontinuing chronic tamoxifen therapy, the serum elimination of metabolites X, Y and E paralleled that of tamoxifen, whereas that of metabolite Z did not. The serum elimination of tamoxifen and metabolites X and B was increased by amino-glutethimide treatment, whereas that of metabolites Z, Y, and E was not.
摘要
在停止长期他莫昔芬治疗的乳腺癌患者中，代谢物X、Y和E的血清清除情况与他莫昔芬的相似，而代谢物Z并非如此。氨基谷氨酰胺治疗可增加他莫昔芬以及代谢物X和B的血清清除率，而代谢物Z、Y和E的血清清除率则不受影响。
Zotero 插件